Fusion Antibodies: results underwhelm
Fusion Antibodies (LON: FAB), specialists in pre-clinical antibody discovery, for both therapeutic drug and diagnostic applications, underwhelmed with its interim results for the six months ending 30 September 2020, at least for a business with its high rating – the current market capitalisation is £29m.
Revenues rose 8.5% of £1.90m with losses remaining stable at £0.47m.
They expanded their R&D programme in the period by 50% to £271k to include a COVID-19 target…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on Advanced Medical Solutions
19/09/2024 · Company Insights
News covered here includes our assessment of results from a company operating in the healthcare sector.…
17/07/2024 · Company Insights
News covered here includes our assessment of excellent results from a provider of a diverse range…
More on Argentex Group PLC
19/09/2024 · Company Insights
A new management team is executing its plan to accelerate growth, making a number of significant new…
03/02/2024 · Podcasts
In this episode of the Investor’s Champion Podcast, Chris and Lee run through key news from…
More on Frasers Group
01/10/2024 · Company Insights
One of AIM’s largest companies seems inclined to accept a private equity funded offer, with an…
05/01/2024 · Portfolio
Our portfolio company covered here dominates the market for athletic footwear, but is it the best…
More on Fusion Antibodies PLC
20/11/2020 · Company Insights
Mike Ashley’s Frasers has upped its stake in Mulberry and is obliged to contemplate a full…
28/04/2020 · Company Insights
Announcements included an update from from Burford Capital, which saw its shares bounce strongly, but we still…
More Company Insights
Strong cash generators impress
Well-supported equity raise should reassure
A bright start to the week for these AIM companies
More on Advanced Medical Solutions
More on Argentex Group PLC
More on Frasers Group
More on Fusion Antibodies PLC
More Company Insights